Company Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
The company’s product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency.
It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B.
In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials.
Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial.
Arrowhead Pharmaceuticals, Inc. has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No.
3) Limited; Horizon Therapeutics Ireland DAC; Takeda Pharmaceutical Company Limited; and with Amgen Inc. The company was founded in 2003 and is headquartered in Pasadena, California.
| Country | United States |
| Founded | 2003 |
| IPO Date | Jun 16, 1993 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 609 |
| CEO | Christopher Anzalone |
Contact Details
Address: 177 East Colorado Boulevard, Suite 700 Pasadena, California 91105 United States | |
| Phone | 626 304 3400 |
| Website | arrowheadpharma.com |
Stock Details
| Ticker Symbol | ARWR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0000879407 |
| CUSIP Number | 04280A100 |
| ISIN Number | US04280A1007 |
| Employer ID | 46-0408024 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Christopher R. Anzalone Ph.D. | Chairman, Chief Executive Officer and President |
| Patrick O'Brien J.D., PharmD | Chief Operating Officer, General Counsel and Secretary |
| Dr. James C. Hamilton M.D., MBA | Chief Medical Officer and Head of Research & Development |
| Dr. Mark M. Davis Ph.D. | Founder and Founder and Director of Insert Therapeutics Inc & Calando |
| Daniel J. Apel | Chief Financial Officer |
| Dr. Vincent Anzalone CFA | Head of Investor Relations and Vice President |
| Howard Lovy | Director of Communications |
| Dr. Bruce D. Given M.D. | Chief Medical Scientist |
| Dr. Mark Seefeld | Head of Toxicology and Vice President |
| Aaron Tan | Head of Tax |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 29, 2025 | SCHEDULE 13G/A | Filing |
| Jul 10, 2025 | 144 | Filing |
| May 13, 2025 | SCHEDULE 13G | Filing |
| May 12, 2025 | 8-K | Current Report |
| May 12, 2025 | 10-Q | Quarterly Report |
| Apr 23, 2025 | SCHEDULE 13G/A | Filing |
| Apr 15, 2025 | 8-K | Current Report |
| Apr 11, 2025 | 144 | Filing |
| Apr 10, 2025 | 144 | Filing |
| Apr 9, 2025 | 144 | Filing |